Great Efficacy of Afatinib in a Patient with Lung Adenocarcinoma Harboring EGFR L833V/H835L Mutations: A Case Report
Authors:
Open Access
- 1 October 2020
- journal article
- case report
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. ume 13, 10689-10692
Abstract
Uncommon mutations account for 10– 15% of epidermal growth factor receptor (EGFR) mutations in patients with non-small-cell lung cancer (NSCLC). Most of them are proved to be sensitive or resistant to EGFR-tyrosine kinase inhibitors (TKIs). However, there is insufficient evidence for other less common types of EGFR mutations, such as complex mutations. Here, we present a 65-year-old never-smoking male who was diagnosed with stage IV lung adenocarcinoma. A rare L833V/H835L complex mutation in exon 21 of EGFR was detected in plasma and pleural effusion by next generation sequencing (NGS). Afatinib was used as first-line therapy and showed very good efficacy. To date, the patient is still benefited from afatinib treatment for a total of 10 months, with no signs of disease progression. Our case suggests that a comprehensive screening for EGFR mutations should be conducted before treatment in clinical practice, and afatinib could be a first-line treatment option in NSCLC patients harboring H833V/H835L mutations.Keywords
This publication has 20 references indexed in Scilit:
- A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancerLung Cancer, 2017
- Worldwide Frequency of Commonly Detected EGFR MutationsArchives of Pathology & Laboratory Medicine, 2017
- EGFR L858M/L861Q cis Mutations Confer Selective Sensitivity to AfatinibJournal of Thoracic Oncology, 2017
- Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective StudyPLOS Medicine, 2016
- A Triple Rare E709K and L833V/H835L EGFR Mutation Responsive to an Irreversible Pan-HER Inhibitor: A Case Report of Lung Adenocarcinoma Treated with AfatinibJournal of Thoracic Oncology, 2016
- Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6The Lancet Oncology, 2015
- A comparison of epidermal growth factor receptor mutation testing methods in different tissue types in non-small cell lung cancerInternational Journal of Molecular Medicine, 2014
- A Sequential Method of Epidermal Growth Factor Receptor Mutation Detection Reduces False Negatives: A New Case With Doublet Mutations of L833V and H835L in ChinaClinical Lung Cancer, 2013
- Compound EGFR Mutations and Response to EGFR Tyrosine Kinase InhibitorsJournal of Thoracic Oncology, 2013
- Good Response to Gefitinib in a Lung Adenocarcinoma Harboring a Heterozygous Complex Mutation of L833V and H835L in Epidermal Growth Factor Receptor GeneJournal of Clinical Oncology, 2011